In partnership with

  • Conferences
  • Disease Areas
  • News
  • Articles
  • Contact
    • twitter
    Highlights from

    EAN 2020

    European Academy of Neurology

    Virtual 23 - 26 May 2020

    Articles

    Letter from the Editor

    Letter from the Editor

    Alzheimer's Disease and Other Dementias

    Non-Alzheimer’s disease pathophysiology in the elderly

    Novel genetic association with resistance to ERC tau deposition

    News on AD biomarkers

    Diastolic dysfunction novel risk factor for cognitive impairment

    Epilepsy

    Avoidable epilepsy-related mortality remains high

    How genetic testing can contribute to epilepsy management

    Cenobamate effective in focal epilepsy

    Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome

    Prevalence of autoantibodies in epilepsy almost 10%

    Parkinson's Disease

    White matter matters in Parkinson’s disease

    Sleep disorders mark PD progression

    Long-term safety of ND0612 in idiopathic PD

    Directional DBS superior to omnidirectional DBS

    Stroke

    Benefits of statins to prevent stroke outweigh risks

    Extubation after thrombectomy: the sooner, the better

    Thrombus location and length predictors of early neurological deterioration

    Endovascular treatment in large vessel occlusion stroke patients treated with OAC

    Early edoxaban may be safe after cardioembolic stroke

    Headache and Pain

    Small fibre pathology as biomarker for fibromyalgia

    Migraine as a cyclical functional disorder

    Reassuring real-world safety profile of 3 CGRP inhibitors

    Long-term cardiovascular safety of erenumab

    Real-world data for erenumab in Germany

    Eptinezumab in chronic migraine and medication-overuse headache

    Fremanezumab tolerability in cardiovascular patients with migraine

    Effects of galcanezumab on health-related quality of life

    Unmet needs and pipeline

    Multiple Sclerosis

    Imaging to evaluate remyelination and neuroprotection

    MRI-based clustering of MS patients

    Serum NfL predicts long-term clinical outcomes in MS

    Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS

    High NEDA rates after 2 years of ocrelizumab

    Two trials comparing relapsing MS treatments

    Switching from natalizumab to moderate- versus high-efficacy DMT

    Results of compounds in late stages of development

    Alemtuzumab efficacy and safety data of over 9 years

    Fampridine treatment results in routine clinical practice

    Air pollution is a possible risk factor for MS

    Neuromyelitis Optica Spectrum Disorder

    Genetic association studies in NMOSD needed

    Eculizumab in NMOSD: the PREVENT study

    Long-term safety of satralizumab consistent with double-blind periods

    Neuromuscular Disorders

    Biomarkers predicting motor function in SMA

    Sustained benefits of avalglucosidase alfa in late-onset Pompe disease

    Efficacy and safety of rituximab in refractory MG corroborated

    Top image: @ iStockPhoto: koto_feja

    The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

    BACK TO TOP